The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Background The comparative effectiveness of glucose-lowering medications for use with
metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is …

Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …

Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …

Background Despite advancements in care, many people with type 2 diabetes do not meet
treatment goals; thus, development of new therapies is needed. We aimed to assess …

1. Specific recommendations for prevention strategies often depend on the ischemic
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …

Background Data are lacking on the comparative effectiveness of commonly used glucose-
lowering medications, when added to metformin, with respect to microvascular and …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2· 4 mg versus semaglutide 1· 0 mg (the dose approved for …